Case report: Successful treatment of advanced urothelial carcinoma with trophoblastic differentiation using Tislelizumab and Disitamab vedotin
The prognosis of advanced urothelial carcinoma with trophoblastic differentiation is unfavorable, and the available therapeutic options are limited. Combining Tislelizumab with Disitamab vedotin presents a promising anti-tumor strategy that warrants further investigation.
Authors
- Yujuan Zhou (ORCID: https://orcid.org/0009-0007-1536-4623)
- Han Chen (ORCID: https://orcid.org/0000-0002-8970-5941)
- Zheng Wu
- Yaqian Han (ORCID: https://orcid.org/0009-0005-7733-3799)
- Lin Liu
Institutions
- Central South University (CN)
- Hunan Cancer Hospital (CN)
Publication Details
- Journal
- Heliyon
- Published
- 2024-09-26
- DOI
- https://doi.org/10.1016/j.heliyon.2024.e38518
- Primary Topic
- Bladder and Urothelial Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00